首页|Clinical efficacy of Xuebijing injection for the treatment of sepsis:A retrospective cohort study

Clinical efficacy of Xuebijing injection for the treatment of sepsis:A retrospective cohort study

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:The objective of this study was to investigate the clinical efficacy and safety of treating sepsis patients with Xuebijing injection(XBJI).Methods:We conducted a retrospective analysis of 418 patients who experienced severe infections and were treated with XBJI from June 2018 to June 2021.Propensity score matching was used to match the patient cases.The study population included 209 pairs of cases(418 individuals),and the analysis included data from before and after a 14-day course of treatment with carbapenem alone,or carbapenem with XBJI.Results:There were no significant differences in the 14-day mortality or length of hospital stay(P＞0.05)between the two groups.The combined treatment group had more patients with C-reactive protein that returned to normal levels(compared to baseline)than the non-combined treatment group(14.4％vs 8.1％;odds ratio[OR]:0.528;95％confidence interval[CI]:0.282-0.991;P=0.026).Similarly,the combined treatment group had higher procalcitonin attainment rate(55.0％vs 39.7％;OR:0.513;95％CI:0.346-0.759;P=0.001)than the non-combined treatment group.Further,more patients in the combined treat-ment group achieved normal creatinine levels than in the non-combined treatment group(64.1％vs 54.1％;OR:0.659;95％CI:0.445-0.975;P=0.037).Conclusion:The combination of XBJI with carbapenem did not reduce the 14-day mortality rate of patients with severe infection,but it was able to reduce the level of inflammatory factors in patients with sepsis,and had a protective effect on liver and kidney function.

Xuebijing injectionSepsisInflammatory factorsSeptic shockMortality

Zhao-tang Gong、Hong-xin Yang、Ben-ben Zhu、Huan-huan Liu、Guleng Siri

展开 >

Department of Pharmacy,Inner Mongolia Autonomous Region People's Hospital,Hohhot 010017,Inner Mongolia Autonomous Region,China

Department of Pharmacy,Inner Mongolia Medical University,Hohhot 010110,Inner Mongolia Autonomous Region,China

Department of Pharmacy,Peking University Cancer Hospital(Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University,Hohhot 010020,Inner Mongolia Autonomous Region,China

Department of Pharmacy,Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100010,China

Inner Mongolia Academy of Medical Sciences,Hohhot 010017,Inner Mongolia Autonomous Region,China

展开 >

2024

10.1016/j.joim.2024.08.006

结合医学学报(英文版)
上海市中西医结合学会,上海长海医院

结合医学学报(英文版)

CSTPCD
影响因子：0.711
ISSN：2095-4964
年,卷(期)：2024.22(6)